SANTEN PHARMACEUTICAL CO.,LTD. (4536) Stock Price

Santen Pharmaceutical is engaged in the research and development, manufacturing, and sales of pharmaceutical products. The Santen Pharmaceutical Group consists of Santen Pharmaceutical Co., Ltd., 33 consolidated subsidiaries, and one affiliate accounted for using the equity method. The primary business is pharmaceuticals, with a particular focus on the ophthalmology sector.

Santen Pharmaceutical's business is divided into four segments: prescription pharmaceuticals, over-the-counter pharmaceuticals, medical devices, and other. The prescription pharmaceutical business operates in Japan, China, Asia, and the EMEA region (Europe, Middle East, and Africa). Key companies include Santen Eye Care Co., Ltd. in Japan and Santen Investment (China) Co., Ltd. in China.

The over-the-counter pharmaceutical business operates in Japan and Asia. Santen Pharmaceutical plays the primary role in Japan, while Taiwan Santen Pharmaceutical Co., Ltd. serves as the main company in Asia. This enables the company to provide products to a broad range of consumers.

The medical device business operates in Japan and the EMEA region. Key companies in the EMEA region include Santen Oy and Santen S.A.S. Through these operations, the company develops and sells ophthalmology medical devices. The other business segment includes Advanced Vision Science, Inc., which conducts advanced technology development.

Through these business operations, Santen Pharmaceutical aims to support the visual health of people worldwide. By expanding operations across regions, the company strengthens its competitive position in the global market.

Santen Pharmaceutical is a specialty company focused on the ophthalmology field, dedicated to providing valuable products and services to patients and healthcare professionals worldwide, with the goal of realizing "Happiness with Vision." Over 130 years, the company has pursued eye health maintenance and improvement, and currently supports the eye health of approximately 50 million people across more than 60 countries and regions.

The company has formulated a medium-term management plan for fiscal years 2025–2029 and is implementing strategies with a view toward long-term growth through 2035. Through strengthening product development and revenue foundations in the ophthalmology field, Santen pursues global growth and drives innovation in eye care.

As its growth strategy, Santen has established six initiatives. These include establishing leadership in overseas markets, creating markets for myopia and blepharoptosis, strengthening the Rx portfolio, establishing stable supply systems, optimizing costs, and enhancing human capital and digital capabilities.

For fiscal year 2029, the company targets sales revenue of 400 billion yen, core operating profit of 80 billion yen, ROE of 14% or higher, and double-digit EPS growth. For shareholder returns, the company aims for a dividend payout ratio of 40% while implementing dividend increases and executing flexible share buybacks.

Santen is pursuing sustainable growth by advancing social contribution and strengthening its business foundation. The company is actively promoting 13 materiality issues, including the creation of products that contribute to eye health, quality assurance of products, and sustainable procurement.